Group:SMART:P-glycoprotein: Why Cancer Drugs Fail: Difference between revisions
Grace Wang (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 46: | Line 46: | ||
Verapamil, a P-gp inhibitor, helps anti-cancer drugs go into cells by “distracting” P-gp; thus, decreasing P-gp’s activity on anti-cancer drugs. For example, when an anticancer drug such as, Vincristine, is taken with Verapamil, the effects are beneficial to the patient because P-gp is focused on taking Verapamil so that Vincristine can get into the cell. This offers promise in increasing the effectiveness of chemotherapy in patients with cancer through the combined use of anticancer drugs with P-glycoprotein inhibitors (in doses determined for each individual). | Verapamil, a P-gp inhibitor, helps anti-cancer drugs go into cells by “distracting” P-gp; thus, decreasing P-gp’s activity on anti-cancer drugs. For example, when an anticancer drug such as, Vincristine, is taken with Verapamil, the effects are beneficial to the patient because P-gp is focused on taking Verapamil so that Vincristine can get into the cell. This offers promise in increasing the effectiveness of chemotherapy in patients with cancer through the combined use of anticancer drugs with P-glycoprotein inhibitors (in doses determined for each individual). | ||
==Additional Resources== | |||
For additional information, see: [[Cancer]] | |||
<br /> | |||